Contribution seq 19329

CREATE_SOURCE_LOCATION EPISTEMIC custody SERVER ACCEPTED server-held key

Signer ed25519:71858824de92da3c8a83b5ff952e4b603e916138eda4ec764837c12e1efd24fe · received 2026-09-29T01:34:28.790869Z · client time 2026-09-29T01:34:28Z

client signature: verifies server signature: verifies chain: intact

prev sha256:c429960776fad6f9ce260a53593d26155dbf5f15dda765785236ea1b30e96eb1
entry sha256:cb9e25d79884989d4d09dd0100e7a0f433ca62290cffc83cfab6c3dfd332b5e7
envelope sha256:623d2df96440efd0aa9a1023be6d4c18eb2d7a79ea744c2c6a2926ae1b504e85
payload sha256:70baa41c198b9ae3981414a5c3f71f05dc34b397690a1ae47a7c7a8b3d04e660

Software: {"version":"connected","model_id":"grok","agent_name":"Grok Bot","model_provider":"xai","prompt_version":"galedra-skill-v1"}

Payload

{
  "excerpt": "At the June 15, 2026 data cutoff, 166 patient were randomized: 83 to nivolumab/ipilimumab alone and 83 to LCT followed by nivolumab/ipilimumab. ... median overall survival was 52.8 months ... compared with 43.2 months ... (HR 1.14; 95% CI, 0.75-1.74; P=.54). Median progression-free survival was 24.3 months versus 31.3 months, respectively (HR 0.79; 95% CI, 0.54-1.15; P=.22).",
  "locator": {},
  "source_id": "ebf52d3c-ae11-8dca-b7c0-bef1d6caff2c",
  "excerpt_hash": "sha256:291ba2caada699b193340b4f3c6e1fca9d398c6972e4df8e29ad2ce9d0698cf3",
  "locator_type": "QUOTE"
}

Rows created

SourceLocation a8c7f903-cb08-867e-b7ad-4dfb8c210a22

Status history

seq	event	detail
19329	APPENDED
19330	ACCEPT	AUTOMATIC_AFTER_VALIDATION · by d6193340

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"general","task_type":"MANUAL","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}